Pfizer LimitedQ1 FY27 Results & Financial Update
Pfizer Limited: Q1 FY27 standalone results and company financials – revenue ₹653.17 Cr, PAT ₹204.47 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Pfizer price & chart
Market price₹4,046.20
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Pfizer Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Total expenses for the quarter stood at Rs. 421.33 crore, which included Rs. 105.02 crore in cost of materials consumed, Rs. 182.89 crore in purchases of stock-in-trade, and an inventory change benefit of Rs. 47.80 crore.
Employee benefits expense for the quarter was recorded at Rs. 82.08 crore, while finance costs remained modest at Rs. 1.46 crore and depreciation and amortization expenses stood at Rs. 14.26 crore.
The company registered a profit before tax (PBT) of Rs. 276.68 crore for the quarter, with no exceptional items recorded during this period.
Tax expenses for the quarter aggregated to Rs. 72.19 crore, consisting of Rs. 70.93 crore in current tax and Rs. 1.28 crore in deferred tax.
Net profit after tax (PAT) for the quarter settled at Rs. 204.47 crore, resulting in basic and diluted earnings per share (EPS) of Rs. 44.69.
Total expenses for the quarter stood at INR 421.33 crore, driven by consumption of materials, purchases of stock-in-trade, employee benefit expenses, depreciation, and other overheads.
01 · Business model
What does Pfizer do?
Pfizer Limited operates within the pharmaceuticals sector, engaged in the manufacture, marketing, and distribution of a wide range of pharmaceutical products and healthcare formulations.
The company's primary revenue streams are generated through domestic sales of pharmaceutical formulations, encompassing both manufactured goods and traded stock-in-trade.
Pfizer Limited operates as a single business segment focused exclusively on pharmaceuticals and maintains no subsidiary, associate, or joint venture companies as of June 30, 2026.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹653.17 Cr |
| Total income | ₹698.01 Cr |
| Profit before tax | ₹276.68 Cr |
| Profit after tax | ₹204.47 Cr |
| EPS | ₹44.69 |
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations of Rs. 653.17 crore was driven by domestic distribution and sales of pharmaceutical products and traded formulations.
Other income added Rs. 44.84 crore to the top-line, resulting in a total quarterly income of Rs. 698.01 crore.
Revenue from operations for the quarter stood at INR 653.17 crore.
Other income contributed INR 44.84 crore to the total income of INR 698.01 crore for the quarter.
What drove margins
Direct operating costs included Rs. 105.02 crore of material consumption and Rs. 182.89 crore of stock-in-trade purchases, offset by a positive inventory movement of Rs. 47.80 crore.
Employee benefit expenses stood at Rs. 82.08 crore, while other expenses were maintained at Rs. 83.42 crore.
Finance costs were controlled at Rs. 1.46 crore, and depreciation and amortization charges accounted for Rs. 14.26 crore.
Cost of materials consumed was INR 105.02 crore and purchases of stock-in-trade were INR 182.89 crore, offset by a positive inventory change of INR 47.80 crore.
Employee benefits expense stood at INR 82.08 crore, finance costs were INR 14.60 crore, depreciation and amortization expenses were INR 14.26 crore, and other expenses amounted to INR 83.42 crore.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates entirely within a single reportable segment, 'Pharmaceuticals'.
The company operates exclusively in one business segment, which is pharmaceuticals; hence, segment reporting is not applicable.
05 · Strategy & new businesses
How the company is trying to change its growth mix
The company maintains a standalone operational scope with no subsidiaries, associates, or joint ventures.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Auditor Review
The financial results for the quarter ended June 30, 2026, were subjected to a limited review by statutory auditors B S R & Co. LLP, with an unmodified review report.
07 · Key Q&A
The quarter, answered directly
What does Pfizer do?
Pfizer Limited operates within the pharmaceuticals sector, engaged in the manufacture, marketing, and distribution of a wide range of pharmaceutical products and healthcare formulations.
What is the clearest takeaway from Q1 FY27?
Total expenses for the quarter stood at Rs. 421.33 crore, which included Rs. 105.02 crore in cost of materials consumed, Rs. 182.89 crore in purchases of stock-in-trade, and an inventory change benefit of Rs. 47.80 crore.
What drove revenue or demand?
Revenue from operations of Rs. 653.17 crore was driven by domestic distribution and sales of pharmaceutical products and traded formulations.
What mattered most for margins or profitability?
Direct operating costs included Rs. 105.02 crore of material consumption and Rs. 182.89 crore of stock-in-trade purchases, offset by a positive inventory movement of Rs. 47.80 crore.
What changed operationally beyond the headline numbers?
The company maintains a standalone operational scope with no subsidiaries, associates, or joint ventures.
What should the next disclosure help confirm?
Monitor upcoming quarterly financial filings to evaluate revenue growth trends and operating margin trajectories.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Performance: Monitor upcoming quarterly financial filings to evaluate revenue growth trends and operating margin trajectories.
- 02
Regulatory and Statutory Updates: Monitor ongoing developments pertaining to regulatory changes and statutory enactments such as the New Labour Codes.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.